Clinician perspectives on current issues in lung cancer drug development

Saiama N. Waqar, Philip D. Bonomi, Ramaswamy Govindan, Fred R. Hirsch, Gregory J. Riely, Vassiliki Papadimitrakopoulou, Dickran Kazandjian, Sean Khozin, Erin Larkins, Dane J. Dickson, Shakun Malik, Leora Horn, Andrea Ferris, Alice T. Shaw, Pasi A. Jänne, Tony S.K. Mok, Roy Herbst, Patricia Keegan, Richard Pazdur, Gideon M. Blumenthal

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Recent advances in molecularly targeted therapy and immunotherapy offer a glimmer of hope for potentially realizing the dream of personalized therapy for lung cancer. This article highlights current questions in clinical trial design, enrollment strategies and patient focused drug development, with particular emphasis on unique issues in trials of targeted therapy and immunotherapy. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.

Original languageEnglish
Pages (from-to)1387-1396
Number of pages10
JournalJournal of Thoracic Oncology
Issue number9
StatePublished - 2016


  • Clinical trials
  • Immunotherapy
  • Lung cancer
  • Targeted therapy


Dive into the research topics of 'Clinician perspectives on current issues in lung cancer drug development'. Together they form a unique fingerprint.

Cite this